[go: up one dir, main page]

Pärkkä et al., 2006 - Google Patents

Comparison of MRI and positron emission tomography for measuring myocardial perfusion reserve in healthy humans

Pärkkä et al., 2006

View PDF
Document ID
7556066746053553249
Author
Pärkkä J
Niemi P
Saraste A
Koskenvuo J
Komu M
Oikonen V
Toikka J
Kiviniemi T
Knuuti J
Sakuma H
Hartiala J
Publication year
Publication venue
Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine

External Links

Snippet

Myocardial perfusion reserve (MPR, defined as the ratio of the maximum myocardial blood flow (MBF) to the baseline) is an indicator of coronary artery disease and myocardial microvascular abnormalities. First‐pass contrast‐enhanced magnetic resonance imaging …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/0275—Measuring blood flow using tracers, e.g. dye dilution
    • A61B5/02755—Radioactive tracers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences, Generation or control of pulse sequences ; Operator Console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7285—Specific aspects of physiological measurement analysis for synchronising or triggering a physiological measurement or image acquisition with a physiological event or waveform, e.g. an ECG signal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radiowaves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radiowaves involving electronic or nuclear magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radiowaves
    • A61B5/053—Measuring electrical impedance or conductance of a portion of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/50—Clinical applications
    • A61B6/507—Clinical applications involving determination of haemodynamic parameters, e.g. perfusion CT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Similar Documents

Publication Publication Date Title
Pärkkä et al. Comparison of MRI and positron emission tomography for measuring myocardial perfusion reserve in healthy humans
Vu et al. Quantitative perfusion mapping with induced transient hypoxia using BOLD MRI
Hopkins et al. Imaging lung perfusion
Lee et al. Myocardial T1 and extracellular volume fraction mapping at 3 tesla
Lin et al. Quantitative measurements of cerebral blood flow in patients with unilateral carotid artery occlusion: a PET and MR study
Karamitsos et al. Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: insights from cardiovascular magnetic resonance and positron emission tomography
Fritz‐Hansen et al. Quantification of MRI measured myocardial perfusion reserve in healthy humans: a comparison with positron emission tomography
Grandin et al. Absolute CBF and CBV measurements by MRI bolus tracking before and after acetazolamide challenge: repeatabilily and comparison with PET in humans
Yen et al. Test‐retest reproducibility of quantitative CBF measurements using FAIR perfusion MRI and acetazolamide challenge
Pack et al. Comparison of myocardial perfusion estimates from dynamic contrast‐enhanced magnetic resonance imaging with four quantitative analysis methods
Wu et al. Renal perfusion 3-T MR imaging: a comparative study of arterial spin labeling and dynamic contrast-enhanced techniques
Ishida et al. Underestimation of myocardial blood flow by dynamic perfusion CT: explanations by two-compartment model analysis and limited temporal sampling of dynamic CT
Ichihara et al. Quantitative analysis of first‐pass contrast‐enhanced myocardial perfusion MRI using a patlak plot method and blood saturation correction
Jahnke et al. Navigator-gated 3D blood oxygen level–dependent CMR at 3.0-T for detection of stress-induced myocardial ischemic reactions
Michaely et al. Temporal constraints in renal perfusion imaging with a 2-compartment model
Hermoye et al. Calculation of the renal perfusion and glomerular filtration rate from the renal impulse response obtained with MRI
Gebker et al. How we perform myocardial perfusion with cardiovascular magnetic resonance
Tomiyama et al. Quantification of myocardial blood flow with dynamic perfusion 3.0 Tesla MRI: Validation with 15o‐water PET
Mouannes‐Srour et al. Correction for arterial‐tissue delay and dispersion in absolute quantitative cerebral perfusion DSC MR imaging
Mou et al. Evaluation of myocardial microcirculation using intravoxel incoherent motion imaging
Pack et al. Estimating myocardial perfusion from dynamic contrast-enhanced CMR with a model-independent deconvolution method
Koskenvuo et al. Global myocardial blood flow and global flow reserve measurements by MRI and PET are comparable
CA2758393A1 (en) Imaging technique
Ishida et al. Quantification of myocardial blood flow using model based analysis of first‐pass perfusion MRI: Extraction fraction of Gd‐DTPA varies with myocardial blood flow in human myocardium
Papanastasiou et al. Multimodality quantitative assessments of myocardial perfusion using dynamic contrast enhanced magnetic resonance and 15 O-labeled water positron emission tomography imaging